We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Abbott Molecular’s failure to control nonconforming devices and implement complete procedures for accepting or rejecting finished product runs resulted in a warning letter.